Mandate · Fund III · 2024 vintage

We lead
where we have conviction.

We co-invest alongside ARCH, GV, and MPM at Series A through B, leading where we have conviction in the biology. Our $400M fund is backed by Taiho Pharmaceutical's R&D, clinical, and commercialization infrastructure — and a demonstrated route into Asian markets when the asset is ready.

Fund III · 2024 vintage · $400M committed · Series A → B · backed by Taiho Pharmaceutical.01

Active positions24

Lead checks11

Build-to-buy03

Asia bridges05

Portfolio · Fund III · active and realized

Capital where the biology earns it. We lead a single round, we don’t spray, and we publish what we own.

TickerCompanyStageSyndicateStatus

CULPRLCullinan PearlSeries BARCH · GV · MPMAcquired

NXTPRCNextPrecision TherapeuticsSeries Aa16z Bio · ARCHActive

KLPSOKlepsoid BioSeries BFlagship · ARCHActive

HELIX2Helix-2 TherapeuticsSeries AGV · 5AMActive

SOLOMSolomon TherapeuticsSeries AMPM · OrbiMedActive

OXBRGOxbridge BioSeries BARCH · AtlasIPO

METALKMetallosynthSeries Aa16z Bio · GVActive

CYNTHXCynthaxSeries B5AM · MPMBuild-to-buy

VECTRAVectra PharmaSeries AFlagship · ARCHActive

Case study · CULPRL · 2019 → 2024

Founded 2019. Capitalized through Series B alongside ARCH, GV, and MPM. Re-acquired in 2024 for the EGFR exon-20 program.

Build-to-buy in practice — a single-asset NewCo, capitalized, advanced through proof-of-concept, then re-internalized when the data warranted commercial integration.03

Read the full case study →

Syndicate · 2018 — present

We co-invest with operators we trust. The list is short by design.

ARCH Venture Partners
GV
MPM Capital
Flagship Pioneering
a16z Bio + Health
5AM Ventures
OrbiMed
Atlas Venture
Polaris Partners
Third Rock Ventures
F-Prime Capital
NEA

Team · partners

Operators, scientists, and capital allocators. We have all written term sheets, and most of us have run a clinic or a lab.

Plate 01 / 034:5 · B&WPortrait pending — see BRIEFS.md

Plate 01Hiroki Tanaka, MD

Hiroki Tanaka, MD

Managing Partner

Memorial Sloan Kettering
Taiho Pharmaceutical R&D

Plate 02 / 034:5 · B&WPortrait pending — see BRIEFS.md

Plate 02Margaret Chen, PhD

Margaret Chen, PhD

Partner — Therapeutics

Broad Institute
Genentech

Plate 03 / 034:5 · B&WPortrait pending — see BRIEFS.md

Plate 03Daniel Roth

Daniel Roth

Partner — Capital Formation

Lazard Healthcare
Goldman Sachs

Submit · we read every memo

Send the thesis. One paragraph on the biology, one on the round, one on the path to a buyer. We’ll read it.

We are most useful when the biology is first-in-class, the round is Series A or B, and a path to Asia is already part of the thesis.04

thesis@taihoventures.com →